top of page

Diversified Pipeline Driving Near- And Long-Term Value

Through Appili’s unique approach to drug development, we have created a pipeline containing a deliberate mix of close-to-market opportunities that have the potential to provide near-term value with cutting-edge programs that we believe have the potential to transform how we treat many infectious diseases, addressing significant unmet medical needs in patient care.


This approach allows Appili to seek productive collaborations with industry partners and federal government agencies whose objectives align with ours, while pursuing non-dilutive funding sources specifically earmarked for anti-infective development programs.

Pipeline Feb2023.jpg
Screenshot 2023-01-30 150431.jpg
ATI-1701: Tackling a serious bioterrorism threat
Appili Therapeutics Balanced Pipeline.png
ATI-1801: A novel topical antiparasitic product to treat disfiguring infections around the world
ATI-1501: A novel formulation of metronidazole for the growing number of patients who cannot comply with the current standard-of-care
bottom of page